News

23 May: World authorities on prostate cancer to discuss and debate latest advances
  • Much of the on-going research in prostate cancer focuses on patients suffering disease relapse through resistance to conventional hormone therapy. Castration-resistant prostate cancer (CRPC) accounts for between 20 and 30% of all prostate cancers.
  • With significant advances in the treatment of CRPC over recent years, the life expectancy of patients has increased from 12 months in 2004, to 3 – 4 years today.
  • A half-day workshop, organised by the Vall d’ Hebron Institute of Oncology (VHIO), attended by renowned experts within the field, will update on the latest advances in prostate cancer, which has the highest incidence of all cancers in men.
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.